Videos

Finly Zachariah, MD, discusses the rationale behind implementing an AI mortality model at City of Hope, Duarte, California, which enhances the opportunity for patient-clinician discussions on end-of-life preferences, thereby boosting palliative care.

Chakra Chaulagain, MD, discusses findings from a comprehensive examination of National Cancer Database data from 2004 to 2020 regarding the utilization of autologous hematopoietic stem cell transplantation in patients with multiple myeloma.

Francis P. Worden, MD, provides a brief overview of the approval of selpercatinib and what it means for patients with RET fusion-positive thyroid cancer.

Cesar Augusto Perez, MD, discusses one of the top unmet needs that exists in the thyroid cancer space.

As part of its Speaking Out series, Patrick Wagner, MD, discusses safety concerns regarding oncolytic viral therapy.

Cesar Augusto Perez, MD, discusses the efficacy data reported in a phase 2 study of petosemtamab plus pembrolizumab for the first-line treatment of patients with recurrent/metastatic head and neck squamous cell carcinoma.

Sawsan Rashdan, MD, discusses the background, findings, and next steps of a phase 2 study evaluating treatment with osimertinib and consolidative SABR for the treatment of EGFR-mutated NSCLC.

Joshua K. Sabari, MD, and the Oncology Brothers discuss recent findings from the ADRIATIC study focused on durvalumab as consolidation treatment for patients with limited-stage small cell lung cancer.

The Oncology Brothers and Joshua K. Sabari, MD, provide expert perspectives on recent updates from the CROWN trial investigating lorlatinib in treatment-naïve advanced ALK+ non–small cell lung cancer.

Expert perspectives on recent data from the PALOMA-3 study investigating subcutaneous amivantamab in patients with refractory EGFR-mutated advanced non–small cell lung cancer.

Joshua K. Sabari, MD, discusses recent updates from the MARIPOSA study, which is investigating amivantamab plus lazertinib in the first line in patients with EGFR-mutated advanced non–small cell lung cancer.

Following ASCO 2024, Joshua K. Sabari, MD, joins the Oncology Brothers, Rahul Gosain, MD, and Rohit Gosain, MD, to discuss results from the LAURA trial investigating osimertinib following definitive chemoradiotherapy in patients with unresectable stage III non–small cell lung cancer with EGFR mutations.

With their final discussion the panel examines the survival outcomes and risk of thromboembolic/hemorrhagic events from the MAJIC-PV trial, which compared ruxolitinib to best available therapy in polycythemia vera patients resistant or intolerant to hydroxyurea.

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the importance of considering a drug's overall value beyond just its initial price per mg.

This segment discusses the key efficacy and safety considerations from the PROUD-PV and CONTINUATION-PV trials evaluating ropeginterferon alfa-2b as a treatment option for polycythemia vera.

Aditya Bardia, MD, MPH, discusses results of a biomarker analysis of the TROPiCS-02 study of sacituzumab govitecan in HR-positive, HER2-negative metastatic breast cancer presented at ASCO 2024.

William Dale, MD, PhD, discusses the unmet needs of older patients requiring cancer treatment.

David Samuel Dicapua Siegel, MD, shared his perspectives on promising areas of research that could advance the care of patients with myeloma.

Manmeet Ahluwalia, MD, MBA, FASCO, discusses the takeaways from a study which examined the impact of various therapies, including combination treatments, for patients with metastatic renal cell carcinoma.

Mikkael A. Sekeres MD, MS, provides insight on the approval of imetelstat for treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia.

John Mascarenhas, MD, discusses phase 3 of the SENTRY study evaluating the efficacy and safety of selinexor plus ruxolitinib in patients with JAK inhibitor treatment-naive myelofibrosis.

Holly Pederson, MD, and Elisha Hughes, PhD, discuss the findings and implications of a study evaluating risk of triple-negative breast cancer for Black women presented at the 2024 ASCO Annual Meeting.

Mazyar Shadman, discusses the mechanism of action of sonrotoclax and the phase 3 trial titled CELESTIAL-TNCLL, which is evaluating the agent for the treatment of patients with chronic lymphocytic leukemia.

Joseph Greer, PhD, discusses the late-breaking abstract from the 2024 ASCO Annual Meeting evaluating telehealth vs in-person palliative care for patients with advanced non-small cell lung cancer.

Minesh Mehta, MD, discusses positive findings from the phase 3 METIS trial investigating TTFields therapy for brain metastases in NSCLC.

Lynn Schuchter, MD, 2023-2024 ASCO president, discusses her top abstracts from the annual meeting.

Lori J. Wirth, MD, offers advice to oncologists using lenvatinib when treating patients with differentiated thyroid cancer.

As part of its Speaking Out series, Patrick Wagner, MD, discusses eligibility and considerations for oncolytic viral therapies.

Stacey Stein, MD, discusses the patient population and outcomes of the IMbrave150 trial of atezolizumab plus bevacizumab for patients with advanced hepatocellular carcinoma.

Yucai Wang, MD, PhD, discusses the rationale, methods, and design of a study evaluating the efficacy of pembrolizumab when given as both a monotherapy and in combination with B-cell receptor inhibitors for Richter transformation of CLL.